ABBV
$136.87
Abbvie
$3.43
2.57%
ABBV
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  $2.93
Revenue:  $13.47 Bil
Thursday
Jul 27
7:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, April 27, 2023

What do you expect when ABBV reports earnings?
Beat
Meet
Miss

Where is ABBV's stock price going from here?
Up
Flat
Down
Stock chart of ABBV
Analysts
Summary of analysts' recommendations for ABBV
Score
Grade
Pivots
Resistance
$141.53
$139.25
$138.06

$135.78

Support
$134.59
$132.31
$131.12
Tweet
Growth
Description
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsEli LillyMerck & Co.Bristol-Myers SquibbArray TechnologiesJohnson & JohnsonUltragenyx PharmaceuticalPfizer